Universal Beteiligungs und Servicegesellschaft mbH Boosts Position in Innoviva, Inc. $INVA

Universal Beteiligungs und Servicegesellschaft mbH increased its position in shares of Innoviva, Inc. (NASDAQ:INVA) by 838.8% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 115,503 shares of the biotechnology company’s stock after acquiring an additional 103,200 shares during the quarter. Universal Beteiligungs und Servicegesellschaft mbH’s holdings in Innoviva were worth $2,108,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Bank of Montreal Can boosted its holdings in Innoviva by 4.2% in the 2nd quarter. Bank of Montreal Can now owns 18,853 shares of the biotechnology company’s stock valued at $379,000 after purchasing an additional 767 shares during the last quarter. Oregon Public Employees Retirement Fund raised its position in shares of Innoviva by 6.3% during the 3rd quarter. Oregon Public Employees Retirement Fund now owns 13,507 shares of the biotechnology company’s stock valued at $247,000 after buying an additional 800 shares during the period. Teacher Retirement System of Texas lifted its holdings in Innoviva by 5.9% in the second quarter. Teacher Retirement System of Texas now owns 16,053 shares of the biotechnology company’s stock valued at $323,000 after acquiring an additional 889 shares during the last quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS grew its position in Innoviva by 7.6% in the second quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 14,183 shares of the biotechnology company’s stock worth $285,000 after acquiring an additional 1,000 shares during the period. Finally, Ameritas Investment Partners Inc. increased its stake in Innoviva by 18.6% during the second quarter. Ameritas Investment Partners Inc. now owns 6,429 shares of the biotechnology company’s stock worth $129,000 after acquiring an additional 1,007 shares during the last quarter. 99.12% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

INVA has been the subject of a number of recent analyst reports. Weiss Ratings reissued a “buy (b)” rating on shares of Innoviva in a research report on Monday, December 29th. Cantor Fitzgerald lifted their price target on shares of Innoviva from $29.00 to $31.00 and gave the company an “overweight” rating in a research report on Thursday, November 6th. HC Wainwright boosted their price target on shares of Innoviva from $45.00 to $46.00 and gave the company a “buy” rating in a research note on Tuesday, December 16th. Wall Street Zen raised shares of Innoviva from a “buy” rating to a “strong-buy” rating in a research report on Saturday, October 25th. Finally, Zacks Research lowered Innoviva from a “strong-buy” rating to a “hold” rating in a research report on Thursday, November 6th. Five analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $38.80.

Innoviva Trading Up 1.0%

NASDAQ INVA opened at $19.75 on Friday. The company has a debt-to-equity ratio of 0.25, a quick ratio of 13.33 and a current ratio of 14.12. The firm has a market cap of $1.48 billion, a price-to-earnings ratio of 14.42 and a beta of 0.44. The firm has a 50 day simple moving average of $20.16 and a 200-day simple moving average of $19.57. Innoviva, Inc. has a one year low of $16.52 and a one year high of $22.76.

Innoviva (NASDAQ:INVA) last announced its earnings results on Wednesday, November 5th. The biotechnology company reported $1.08 earnings per share for the quarter, topping the consensus estimate of $0.46 by $0.62. The firm had revenue of $107.80 million for the quarter, compared to the consensus estimate of $91.31 million. Innoviva had a net margin of 32.78% and a return on equity of 28.17%. Equities research analysts anticipate that Innoviva, Inc. will post 0.33 EPS for the current fiscal year.

Innoviva Company Profile

Innoviva, Inc, incorporated in Delaware and headquartered in San Francisco, California, is a royalty-focused life sciences company. It acquires, manages and monetizes royalty and license interests in biopharmaceutical products, with a primary emphasis on inhaled respiratory therapies. Innoviva’s portfolio is anchored by royalties on therapies originally developed by its former affiliate, now marketed by GlaxoSmithKline, including several long-acting inhaled products approved for chronic obstructive pulmonary disease (COPD) and asthma.

The company was established through a spin‐out transaction in 2014, separating the royalty assets from a research‐based biopharmaceutical enterprise to create a specialized investment vehicle.